Reginster Jean-Yves
Service de santé publique, d'épidémiologie et économie de la santé, CHU Sart Tilman-Bâtiment B23 B-4000 Liège.
Rev Med Suisse Romande. 2004 Feb;124(2):85-7.
The use of drugs for the treatment of osteoarthritis, with a view to obtain a long-term symptomatic as well as structural benefit, is still in a preliminary state. Nowadays, matricial precursors, such as glucosamine sulfate, are an interesting approach in this indication. They have demonstrated a symptomatic efficacy comparable to that of N.S.A.I.D., with significantly reduced side-effects. Glucosamine sulfate also appears to positively interfere with the structural evolution of osteoarthritis by preventing joint space narrowing which characterizes the evolution of the disease. Encouraging results have also been obtained with chondroitin sulfate and diacerein. As for other molecules, new studies should be undertaken to confirm the results already obtained.
使用药物治疗骨关节炎，以期获得长期的症状缓解以及结构改善，目前仍处于初步阶段。如今，诸如硫酸氨基葡萄糖之类的基质前体，在这一适应症方面是一种值得关注的方法。它们已证明具有与非甾体抗炎药相当的症状缓解疗效，且副作用显著减少。硫酸氨基葡萄糖似乎还通过防止关节间隙变窄（这是该疾病发展的特征），对骨关节炎的结构演变产生积极影响。硫酸软骨素和双醋瑞因也取得了令人鼓舞的结果。至于其他分子，应开展新的研究以证实已取得的结果。
